Biogen has announced plans to invest an additional $2 billion in its existing manufacturing footprint in North Carolina’s Research Triangle Park (RTP). Biogen has invested approximately $10 billion in its North Carolina manufacturing footprint to date, including more than $3 billion in recent years, and this upcoming investment will fuel the continued advancement of Biogen’s late-stage clinical pipeline. 

In the next few years, Biogen says it plans to continue investing in multiple modalities and factories across the company’s two campuses in RTP. These investments will include further expansion of the antisense oligonucleotide capabilities and infrastructure, establishing clinical and commercial multi-platform fill –finish capabilities, and continuing to modernize manufacturing technologies and controls through further advanced automation and artificial intelligence. 

Biogen’s manufacturing operations in North Carolina include seven manufacturing factories across multiple modalities. An eighth plant is currently under construction and will be operational in the second half of 2025. The company’s North Carolina campuses include quality control laboratories to ensure the safety, efficacy, and purity of the medicines we produce. More than 90% of innovator commercial medicines produced by Biogen have manufacturing and quality control testing in the US. Outside the US, Biogen has a smaller manufacturing footprint which supplies certain international markets. In Europe, the company operates one biologics factory in Switzerland and is consolidating certain ex-US fill–finish capabilities in Europe into one site in Ireland. 

Source: Biogen